Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs ...
August 03 2020 - 6:45AM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,”
or “we”), a clinical-stage biopharmaceutical company, today
announced that it will report financial results and provide an
update on its development programs pre-market on August 10, 2020.
Reata’s management will host a conference call
on August 10, 2020 at 8:30 a.m. ET. The conference call will
be accessible by dialing (800) 708-4539 (toll-free domestic) or
(847) 619-6396 (international) using the access code:
49873533. The webcast link is
https://edge.media-server.com/mmc/p/hr8ew88f.
Second quarter 2020 financial results to be
discussed during the call will be included in an earnings press
release that will be available on the company’s website shortly
before the call at http://reatapharma.com/investors/ and which will
be available for 12 months after the call. The audio
recording and webcast will be accessible for at least 90 days after
the event at http://reatapharma.com/investors/.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone
methyl (“bardoxolone”) and omaveloxolone, target the important
transcription factor Nrf2 that promotes the resolution of
inflammation by restoring mitochondrial function, reducing
oxidative stress, and inhibiting pro-inflammatory signaling.
Bardoxolone and omaveloxolone are investigational
drugs, and their safety and efficacy have not been established by
any agency.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:Vinny JindalVice President, Corporate
Communications and Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024